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AbstrACt
Introduction Zika virus (ZIKV) infection during pregnancy 
is a known cause of microcephaly and other congenital 
and developmental anomalies. In the absence of a ZIKV 
vaccine or prophylactics, principal investigators (PIs) 
and international leaders in ZIKV research have formed 
the ZIKV Individual Participant Data (IPD) Consortium 
to identify, collect and synthesise IPD from longitudinal 
studies of pregnant women that measure ZIKV infection 
during pregnancy and fetal, infant or child outcomes.
Methods and analysis We will identify eligible studies 
through the ZIKV IPD Consortium membership and a 
systematic review and invite study PIs to participate in 
the IPD meta-analysis (IPD-MA). We will use the combined 
dataset to estimate the relative and absolute risk of 
congenital Zika syndrome (CZS), including microcephaly 
and late symptomatic congenital infections; identify and 
explore sources of heterogeneity in those estimates 
and develop and validate a risk prediction model to 
identify the pregnancies at the highest risk of CZS or 
adverse developmental outcomes. The variable accuracy 
of diagnostic assays and differences in exposure and 
outcome definitions means that included studies will 
have a higher level of systematic variability, a component 
of measurement error, than an IPD-MA of studies of an 
established pathogen. We will use expert testimony, 
existing internal and external diagnostic accuracy 
validation studies and laboratory external quality 
assessments to inform the distribution of measurement 
error in our models. We will apply both Bayesian and 
frequentist methods to directly account for these and other 
sources of uncertainty.
Ethics and dissemination The IPD-MA was deemed 
exempt from ethical review. We will convene a group of 
patient advocates to evaluate the ethical implications and 
utility of the risk stratification tool. Findings from these 
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analyses will be shared via national and international conferences and 
through publication in open access, peer-reviewed journals.
trial registration number PROSPERO International prospective register 
of systematic reviews (CRD42017068915).
IntroduCtIon
Zika virus (ZIKV) infection during pregnancy is an 
acknowledged cause of microcephaly and other forms of 
fetal brain defects and disability.1 2 ZIKV is an arbovirus in 
the genus Flavivirus that is usually transmitted through the 
female Aedes aegypti mosquito. Aedes aegypti is also the main 
vector for dengue (DENV), urban yellow fever (YF) and 
chikungunya viruses. The Asian strain of ZIKV has been 
shown to replicate in the placenta and fetal brain;3 ZIKV 
transmitted from mother to fetus during pregnancy may 
have a detrimental effect on fetal brain development.4–6 
Microcephaly, generally defined as a 2–3 SD reduc-
tion from the mean head circumference,7 8 is caused by 
infections during pregnancy, maternal diet, drug abuse, 
genetic factors or environmental exposures.9 10 Micro-
cephaly (congenital or acquired) may be associated with 
developmental delays: intellectual, hearing and visual 
impairment and epilepsy.11 The causal relation between 
ZIKV and a spectrum of fetal anomalies that includes 
microcephaly, now known as congenital Zika syndrome 
(CZS),12 has been supported through several case-con-
trol;13 14cohort15 16 and surveillance studies;17 animal and 
cell studies18 and through two systematic reviews of the 
evidence for causality that considered all study designs.1 2 
The relation between ZIKV infection during pregnancy 
and miscarriage (pregnancy loss <20 weeks gestation) 
and fetal loss (pregnancy loss ≥20 weeks gestation) is still 
under investigation.
Prior to the 2013–2016 epidemic waves, ZIKV infection 
was known clinically as a mild illness characterised by 
symptoms shared with other arboviruses, including macu-
lopapular rash, headache, fever, non-purulent conjuncti-
vitis and/or joint and muscle pain.19 During the 2015–2016 
ZIKV outbreak in Brazil, which extended to a number 
of other Latin American countries, there was a sharp 
increase in reports of microcephaly and other neonatal 
neurological conditions and in Guillain-Barré syndrome 
(GBS),20–22 an autoimmune neurological disorder. Subse-
quent analysis of medical records collected during and 
after the 2013–2014 ZIKV outbreak in French Polynesia 
identified several ZIKV-linked pregnancies that had not 
been recorded earlier because they ended in elective 
abortion or stillbirth. The reanalysis of medical records 
indicated that the prevalence of both microcephaly 
and GBS had increased in the wake of the outbreak in 
French Polynesia.23 24 The Pan American Health Organi-
zation (PAHO) issued a ZIKV Epidemiological Alert for 
Member States on 7 May 2015,25 the Brazilian Ministry of 
Health (MOH) declared a national public health emer-
gency due to the time and cluster of microcephaly cases 
identified in Northeastern Brazil on 12 November 201526 
and the WHO declared that the clusters of microcephaly 
and related neurological complications represented a 
Public Health Emergency of International Concern on 
1 February 2016.27
ZIKV presents myriad challenges from an epidemi-
ological, virological, diagnostic and outbreak control 
perspective. Diagnosing ZIKV infection is complicated by 
the absence of symptoms in most cases or the presence of 
non-specific symptoms; cross-reactivity with DENV;28 29the 
short window for diagnosing acute infection and the lack of 
point-of-care diagnostics.30 Recent research suggests that 
the relation between ZIKV infection during pregnancy 
and fetopathology may vary by virus genotype or lineage; 
primary versus secondary infection31 and DENV-immune 
status and genotype in the presence of coinfection.29 32 33 
The unequal spatial distribution of microcephaly cases 
has been discussed extensively.34–36 These differences may 
be related to population-level differences in baseline risk 
of adverse fetal outcomes (clinically important heteroge-
neity), differences in study design (eg, inclusion criteria; 
measurement of important cofactors) or to measurement 
error, defined as the difference between the observed and 
actual level of a given variable. Laboratory confirmation 
of ZIKV infection and coinfection differs by diagnostic 
algorithms (eg, definition of positive and negative ZIKV 
diagnostic assay results); factors that affect the regularity 
of testing (eg, provision of incentives, distance from 
testing centre, differences across protocols); popula-
tion-specific distribution of related coinfections; differing 
levels of training of laboratory staff and the accessibility 
of materials and technology (eg, ultrasound, immuno-
assays, reliability panels), among other factors. In addi-
tion to documented difficulties in accurately measuring 
infant head circumference, measurement standards 
for identifying microcephaly differ across populations 
strengths and limitations of this study
 ► This is one of the first applications of an individual participant data 
meta-analysis (IPD-MA) to address public health concerns in the 
context of an emerging pathogen. Lessons learnt from this IPD-MA 
may facilitate the formation of research collaborations to inform the 
public health response to future epidemics.
 ► By using a diversity of populations to develop and validate the risk 
prediction tool that identifies pregnancies at the highest risk of con-
genital Zika syndrome, the IPD-MA provides a real opportunity to 
help inform how clinicians and laboratory scientists communicate 
Zika virus (ZIKV) results to pregnant women and their families.
 ► There is a high degree of variability in the accuracy of diagnostic 
assays for ZIKV, coinfection and outcome ascertainment. Addressing 
this variability will be a challenge and ultimately a limitation of the 
accuracy of IPD-MA results.
 ► There is no gold standard diagnostic assay to detect ZIKV infection 
during pregnancy and few studies have been able to measure fetal 
infection. The statistical methods traditionally used to account for 
measurement error in IPD-MA need to be adapted to account for the 
myriad, correlated sources of uncertainty that arise in the synthesis 
of participant-level data from studies that arise in the context of an 
emerging pathogen.
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and standards themselves may not appropriately classify 
reduced or enlarged head circumference.37 38
Our limited understanding of the absolute risk of 
adverse fetal, infant and child outcomes in ZIKV-infected 
mothers led to calls from several governments suggesting 
that women avoid becoming pregnant for as long as 
2 years.39 40 ZIKV disproportionately affects low-income 
populations residing in areas with poor living condi-
tions.41 The impetus placed on women to delay pregnancy 
as a ZIKV control measure is complicated by the limited 
access to contraception and safe abortion in many of the 
countries and regions with the highest burden of ZIKV-re-
lated microcephaly.42 43 Identifying the risk factors for 
CZS is a global health priority and central for prioritising 
resource allocation for vector control and effective and 
targeted family planning interventions and for improving 
risk counselling for ZIKV-infected pregnant women or 
women planning a pregnancy in endemic areas.
rationale for the individual participant data meta-analysis of 
longitudinal studies of pregnant women
Individual participant data meta-analysis (IPD-MA) is 
the quantitative synthesis of participant-level data from 
included studies, while appropriately accounting for the 
clustering of information at the study level. The proposed 
IPD-MA will combine deidentified, participant-level cohort 
data from different populations of pregnant women to 
identify and quantify the relative importance of different 
predictors of CZS. Individual participant data (IPD) 
have a number of analytic benefits over aggregate data 
meta-analysis (AD-MA), a form of knowledge synthesis that 
combines study-level measures of effect.44 45 IPD facilitate 
the assessment of effect measure modification, the devel-
opment and validation of risk prediction models, and the 
application of a unified analytic approach. In addition to 
using the same statistical model across studies, with IPD 
we can apply the same or similar exclusion criteria, diag-
nostic algorithms, methods for addressing missing data 
and confounding and conduct the same types of sensi-
tivity analyses needed to explore unexplained within- and 
between-study heterogeneity.
Increased precision of estimates
Timely, accurate and reliable predictions are predicated 
on well-designed studies that minimise the risk of bias, 
adequate sample size and the inclusion of a diversity of 
populations. Adequate sample size is crucial for precise 
estimation of the risk of CZS within important subgroups 
(eg, women infected during the first trimester; preg-
nant women with previous or concurrent DENV, CHIKV 
and STORCH (syphilis, toxoplasmosis, rubella, cyto-
megalovirus and herpes) pathogen exposure). Vector 
control measures, including pesticides, public education 
campaigns, the use of drones to detect standing water 
and the introduction of sterilised male vectors to reduce 
Aedes aegypti populations, have been implemented in the 
wake of the 2015/2016 ZIKV epidemics.46–48 Fortunately, 
these measures, in combination with other factors that 
are currently being investigated, seem to have reduced 
the numbers of ZIKV infections during the 2017/2018 
epidemic cycle. While many studies have followed infants 
to the end of their first year, certain developmental mile-
stones can only be assessed after age 249 or when a child 
reaches school age. Leveraging limited data from studies 
with extended follow-up of ZIKV-infected and non-in-
fected women will be essential for estimating the risk of 
more subtle, long-term effects of ZIKV infection during 
pregnancy. By combining data from individual studies, 
the proposed IPD-MA will improve the precision of risk 
estimates.
Identify and quantify the relative importance of effect measure 
modifiers
The benefits of using IPD rather than AD to assess effect 
measure modification and interaction are myriad.50 In a 
one-stage analysis with IPD, subject level data are meta-an-
alysed using the exact binomial distribution; in a two-stage 
analysis of IPD or AD, study-level outcome measures 
are combined assuming asymptomatic normality.51 In a 
one-stage analysis of IPD, study-level and individual-level 
sources of heterogeneity can be assessed concurrently 
and IPD are better able to identify heterogeneity in the 
context of rare events or small studies.50 52 Individual 
studies are often powered to detect the overall effect of 
the exposure rather than subgroup effects. Due to vari-
ations in the characteristics of the affected populations 
and in the potential confounders and effect modifiers 
measured by different studies, it is unlikely that individual 
studies will be powered to definitively quantify the impor-
tance of different sources of heterogeneity in the relation 
between ZIKV infection during pregnancy and adverse 
fetal, infant or child outcomes.
Clinical risk prediction to inform decision-making and resource 
allocation
While there are a number of vaccine trials underway,53 
the development of a ZIKV vaccine is complicated by 
the necessity of testing the vaccine in pregnant women; 
assessing whether the vaccine is associated with devel-
opment of GBS; the difficulties inherent in developing 
an arbovirus vaccine;46 54–56 findings from in vivo studies 
that indicate cross-reactivity between ZIKV and DENV 
or West Nile virus is related to antibody-dependent 
enhancement of ZIKV infection;55 57 58 and by the poten-
tial use of prevention of infection as a vaccine efficacy 
endpoint.59 In this context, identifying the pregnancies 
at the highest risk of adverse neonatal and later devel-
opmental outcomes is critical for effective resource 
allocation and prevention strategies. We will use partic-
ipant-level data to develop and externally validate clin-
ical risk prediction models to facilitate the identification 
of pregnancies that are most likely to result in ZIKV-re-
lated adverse fetal or infant outcomes and longer-term 
developmental delays.
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standardisation and cross-national partnerships to inform the 
public health response to emerging pathogens
Formation of the ZIKV IPD Consortium
The ZIKV IPD Consortium is a global collaboration 
designed to streamline the international response to 
ZIKV. To facilitate cross-country analyses and a coor-
dinated response to ZIKV, representatives from WHO, 
PAHO, the US Centers for Disease Control and Preven-
tion (CDC), the National Institutes of Health (NIH), 
the National Institute of Allergy and Infectious Diseases 
(NIAID), Institut national de la santé et de la recherche 
médicale (INSERM), Institut Pasteur, and the networks 
of Fundação Oswaldo Cruz (Fiocruz), Grupo de Pesquisa 
da Epidemia da Microcefalia (MERG)/ZikaPlan, ZIKAlli-
ance, ZIKAction, the Consortium for the Standardization 
of Influenza Seroepidemiology (CONSISE) and Interna-
tional Severe Acute Respiratory and Emerging Infection 
Consortium (ISARIC) have developed a standardised 
protocol for cohorts of pregnant women and their infants 
exposed to ZIKV to facilitate the proposed IPD-MA; 
identified existing or planned cohorts and prospectively 
introduced cohort principal investigators (PI)s and MOH 
officials to the methodological and public health benefits 
related to IPD-MA in the context of Zika. Many of the 
longitudinal studies and surveillance systems identified 
to date through the review of country-level registries, 
existing literature reviews and ZIKV IPD Consortium 
membership have agreed to contribute deidentified, 
participant level data to the analysis. A complete list of 
the studies and surveillance systems who have agreed to 
contribute data to the ZIKV IPD Consortium led IPD-MA 
is included in  online supplementary table 1.
Standardised protocols for cohorts of pregnant women and their 
infants
A multiplicity of mechanisms for exposure and outcome 
ascertainment as well as differences in the measurement 
of important cofactors are known challenges for the 
meta-analysis of data from individual research studies. To 
minimise the potential for heterogeneity caused by differ-
ences in study inclusion criteria and the measurement of 
ZIKV, infant outcomes and important cofactors, WHO/
PAHO, Institut Pasteur, Fiocruz, CONSISE and ISARIC 
convened an international meeting of ZIKV researchers 
and MOH officials in June 2016 to develop standardised 
protocols and data collection instruments for cohort 
studies of pregnant women and newborns and other 
ZIKV-related studies.60 Standardisation of protocols and 
data collection instruments was intended to minimise 
differences in case ascertainment and data collection 
methods to facilitate data synthesis and the identifica-
tion of sources of heterogeneity in the relation between 
congenital Zika infection and adverse fetal, infant and 
child outcomes. The protocols were made available on 
WHO website in October 2016 (http://www. who. int/ 
reproductivehealth/ zika/ en). The standardised proto-
cols do not include detailed guidance on laboratory 
methods, but testing algorithms were developed by an 
expert panel and made available on the WHO website in 
March 2016 (http://www. who. int/ csr/ resources/ publi-
cations/ zika/ laboratory- testing/ en/). The IPD-MA will 
need to account for the between-study and within-study 
differences in diagnostic assays and testing algorithms.
objECtIvEs of thE IPd-MA
1. Estimate the absolute and relative risks of fetal in-
fection; miscarriage (<20 weeks gestation), fetal loss 
(≥20 weeks gestation), microcephaly and other man-
ifestations of CZS and later developmental delays for 
women who do and do not experience ZIKV infection 
during pregnancy.
2. Identify factors that modify women’s risk of adverse 
ZIKV-related fetal, infant and child outcomes and in-
fants’ risk of infection (eg, gestational age at time of 
infection, clinical or subclinical illness, concurrent or 
prior arbovirus exposure, other congenital infections 
and other posited effect measure modifiers).
3. Use information on the relative importance of differ-
ent effect measure modifiers identified in Objective 2 
to decompose the total effect of ZIKV infection during 
pregnancy on adverse fetal, infant and child outcomes 
into (1) the direct effect of ZIKV; (2) the indirect effect 
of ZIKV as mediated by the effect measure modifier of 
interest (eg, DENV, CHIKV or STORCH pathogens) 
and (3) the effect of the interaction between ZIKV and 
the mediator of interest.
4. Develop and validate a risk prediction tool to identi-
fy pregnant women at a high risk of an adverse ZIKV-
related outcome and to inform couples planning a 
pregnancy, healthcare providers and/or resource mo-
bilisation (eg, vector control strategies; antenatal care; 
open access to contraception).
MEthods And AnAlysIs
This protocol has been drafted in accordance with the 
PRISMA-P Statement (online supplementary table 2).61 
The proposed systematic review and meta-analysis will 
follow the PRISMA-IPD guidelines for the systematic 
review of non-randomised studies.62
step 1. study identification
Eligibility criteria
Eligible studies will use a longitudinal design where 
ZIKV infection is measured in pregnant women prior 
to outcome ascertainment. Eligible studies may include 
cohort studies, case-cohort studies, randomised control 
trials or active surveillance systems, regardless of publi-
cation status. Studies may enrol symptomatic and/or 
asymptomatic women prior to or following a confirmed 
pregnancy. Included studies and active surveillance 
systems will test women for ZIKV infection during preg-
nancy, follow women until the end of pregnancy and 
assess for CZS or related fetal, infant or child outcomes 
(see table 1). We will exclude studies with fewer than 10 
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participants and limit included surveillance systems to 
those that capture country or territory-level active surveil-
lance data (ie, individual hospital active surveillance data 
will not be included). Before sharing participant-level 
data, research studies will be asked to provide documen-
tation of ethics review.
Information sources
ZIKV IPD Consortium
We anticipate that most eligible studies will have been 
identified through the efforts of the ZIKV IPD Consor-
tium. The Consortium is an international initiative that 
is meant to include the PIs from all planned, ongoing or 
completed ZIKV longitudinal studies at the time of this 
review. We have searched clinical trials and ZIKV-related 
databases63 (online supplementary table 3) to identify 
existing or planned longitudinal studies. We have circu-
lated the list of ongoing or planned ZIKV-related longi-
tudinal studies of pregnant women to MOH Officials in 
countries with autochthone ZIKV transmission and to 
PIs of ZIKV cohorts and asked them to update the list as 
necessary.
Systematic review
We will perform a systematic search of biomedical data-
bases for published longitudinal studies and protocols. 
The search strategy is based on Medical Subject Headings 
(MeSH) and text-based search terms for ZIKV, pregnant 
women, infants and children. The search strategy was 
developed in collaboration with an information scien-
tist and adapted for the following electronic databases: 
Embase (Medline), Embase (Ovid) and SCOPUS (see 
online supplementary text 1 for the search strategy for 
Embase (Medline and Ovid). We also will search the 
additional databases listed in online supplementary table 
3 and review the reference lists of published systematic 
reviews and the list of studies produced by a living system-
atic review of ZIKV studies conducted by the University of 
Bern64 to identify additional studies. After removing dupli-
cates from the list of identified studies, two reviewers will 
independently screen the title and abstracts of included 
studies to identify longitudinal studies or active surveil-
lance systems that measure ZIKV infection during preg-
nancy and subsequent fetal, infant or child outcomes. 
Disagreements about study inclusion will be resolved by 
consensus.
Collection of study-level data
We will contact the PIs of eligible studies identified 
through either the ZIKV IPD Consortium or the elec-
tronic searches to invite them to take part in the IPD-MA 
and ask them to provide a copy of their study protocol. We 
will develop and pilot an electronic data extraction form 
to record study-level characteristics for all eligible studies, 
regardless of whether study PIs agree to participate in 
the IPD-MA. Two reviewers will independently review 
protocols and study-related publications to extract data 
on study design; study population; enrolment, follow-up 
and laboratory procedures; assay and specimen type; 
criteria used to define ZIKV infection and timing of infec-
tion and exposure, cofactor and outcome ascertainment 
for all eligible studies. We will ask study PIs for clarifica-
tion if there are outstanding questions or disagreements 
regarding study-level data.
step 2. Collection, review and synthesis of deidentified, 
participant-level data
We will contact the PIs and authors of studies that meet 
our inclusion criteria to request deidentified, partici-
pant-level data on select variables and the associated 
surveys and data dictionaries or codebooks. If study data 
have been imputed, we will request both the original and 
imputed data so that we can apply consistent imputation 
methods across studies and review the imputed dataset 
for validation purposes. To reduce the burden on indi-
vidual studies and ensure clear documentation of all steps 
in the creation of the synthesised dataset, we will use the 
study codebooks or data dictionaries to develop study-spe-
cific code in the statistical language used by the study data 
manager that selects only the study variables required 
for the proposed analyses and removes information that 
could be used to identify individual participants. The 
study’s data manager will apply the code to the original 
dataset. The deidentified, participant-level data will be 
transferred from the study site to Emory University, which 
will serve as the WHO data synthesis partner centre, using 
secure file transfer protocol and will be protected on a 
secure server with standard encryption and by the Emory 
University firewall. Data synthesis-related decisions will 
be reviewed by a ZIKV IPD Consortium membership and 
will be recorded using Jupyter Notebook.65 Researchers 
who are unable or unwilling to provide their participant 
data after at least four attempts at contact by the project 
team over a period of 6 months will be excluded from 
the IPD-MA and we will report the reason for their exclu-
sion. When IPD are not available for a given study, we will 
extract study-level effect estimates from any publications 
to compare study-level estimates from all eligible studies, 
whether or not they provide data for the IPD-MA.
Variables of interest
Despite efforts to develop protocols that can be applied 
across studies, there will be significant cross-study hetero-
geneity in how congenital Zika infection, cofactors 
and outcomes are measured and reported. Exposure, 
outcome variables and posited confounders and effect 
measure modifiers are listed in table 1. Where possible, 
ZIKV and other infections (eg, DENV, CHIKV, STORCH 
pathogens) will be modelled as time-varying, rather than 
time-fixed covariates. Given that the case definitions for 
microcephaly have changed over time (and may change 
during the course of included studies), we will allow for 
the coding of variables with different definitions (ie, WHO 
fetal growth chart,66 Fenton scale,67 INTERGROWTH 
21st Project49). We will ask studies for data on the contin-
uous measures used to make diagnoses (eg, viral load; 
 o
n
 4 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026092 on 18 June 2019. Downloaded from 
8 Wilder-Smith A, et al. BMJ Open 2019;9:e026092. doi:10.1136/bmjopen-2018-026092
Open access 
head circumference) rather than just the diagnoses 
themselves (eg, maternal ZIKV infection, microcephaly). 
Using continuous variables will allow us to test the sensi-
tivity of results to the application of different cutoffs and 
the reference standards used to generate Z-scores. Defi-
nitions for miscarriage, fetal loss and other pregnancy 
outcomes vary across countries. We will explore the sensi-
tivity of project findings to different outcome definitions.
Assessing the integrity of deidentified, participant-level data
We will review the distribution of variables to identify 
potential outliers and to assess the proportion missing 
within each study. We will discuss the distribution of key 
variables with the study data manager to identify and 
address any inconsistencies. If there has been a publica-
tion related to a given longitudinal study, we will attempt 
to replicate table 1 presented in the publication and will 
resolve any inconsistencies with the data manager.
Synthesis of participant-level data
Given that these longitudinal studies and active surveil-
lance systems are part of the global research response to 
an emerging pathogen, there is a high degree of variability 
in the data that have been collected across studies and the 
algorithms that have been applied to define ZIKV expo-
sure, symptoms, components of CZS and so on. Where 
possible, we will ask studies for the individual factors (ie, 
fever, rash) that were used to define certain parameters 
(ie, clinical infection) to ensure cross-study consistency 
in composite markers. Similarly, we will combine the data 
inputs for exposure, cofactor and outcome classification 
algorithms to reduce cross-study differences in the classi-
fication of important factors.
Critical review of study quality
We will use the Cochrane Methodological Quality Assess-
ment of Observational Studies68 and the Q-Coh tool69 
to help describe the risk of bias within non-randomised 
studies and will apply the Cochrane Risk of Bias 2.0 tool 
to assess the risk of bias in randomised controlled trails.70 
Rather than using a score-based bias assessment, a panel 
that includes experts on the evaluation of laboratory 
assays and external quality assessment (EQA); obstet-
rics and perinatal epidemiology will provide a detailed 
description of the role of selection, confounding and 
measurement-related biases within studies.
step 3. statistical analyses
Objectives 1 and 2
Estimate the absolute and relative risks of adverse ZIKV-related 
fetal, infant and child outcomes; identify and quantify relative 
importance of sources of heterogeneity
Estimating the absolute risk of CZS by the gestational 
age of the fetus at the time of infection is as important as 
it is difficult. Early in the outbreak, cohort studies limited 
enrolment to symptomatic pregnant women. While an 
estimated 50%–70% of infections are subclinical, when 
symptoms are detected they generally appear 3–14 days 
after infection.71 For asymptomatic infections, the gesta-
tional age of infection is interval censored because it is 
defined by the last negative and first positive tests for ZIKV. 
Rather than using the midpoint between the last negative 
and first positive ZIKV test, which is known to be biased, we 
will impute the trimester or week that asymptomatic infec-
tions occurred using methods that are routinely applied 
in studies with interval censored covariates in the field of 
perinatal research.72 73 In table 2, we present sample defi-
nitions for the absolute risk of fetal and infant outcomes. 
These definitions will be reviewed prior to analysis and 
publication and we will assess the sensitivity of our results 
to the definition applied. Later developmental outcomes 
(eg, neurodevelopment, cortical auditory processing), 
listed in table 1 as secondary outcomes, will follow a fetus-
es-at-risk approach.74 We will apply censoring to account 
for competing risks where necessary.
We will apply mixed binomial models for binary 
outcomes, and multinomial models for categorical 
outcomes, with a logit link to provide estimates for each 
measure of absolute risk by week or trimester of congen-
ital infection. Because of the differences in baseline risks 
across populations, pooling measures of absolute risk 
Table 2 Definitions applied to estimation of absolute risk of primary fetal and infant outcomes
Outcome Numerator Denominator
Miscarriage Number of miscarriages (pregnancy loss prior 
to 20 weeks gestation)
Total number of pregnancies
Early fetal death Number of pregnancies lost between 
20 and 27 weeks gestation
Total number of pregnancies carried to 20 weeks gestation
Late fetal death Number or pregnancies lost at or following 
28 weeks gestation
Total number of pregnancies carried to 28 weeks gestation
Microcephaly Number of microcephaly cases Total number of pregnancies carried to ≥24 weeks 
gestation, when microcephaly can be assessed by 
ultrasound in ZIKV-infected mothers,38 we will consider all 
pregnancies regardless of whether the pregnancy results in 
a live birth
ZIKV, Zika virus.
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across studies may not be clinically relevant and can even 
be misleading.75 We will combine study-level estimates 
of absolute risk through: (1) a one-stage meta-analysis 
(mixed binomial or multinomial model with a log link) 
that includes study-level sources of heterogeneity and 
a separate intercept for each study to account for addi-
tional cross-study differences in baseline risk and (2) a 
forest plot of study-level estimates of absolute risk that 
does not include a summary meta-analytic estimate.
Absolute measures of effect are considered more 
important for informing clinical practice than relative 
measures.76 We will conduct both (1) a one-stage meta-anal-
ysis where we estimate the relative risk of the aforemen-
tioned outcomes of interest by congenital Zika infection 
across studies and (2) a two-stage meta-analysis where 
we estimate the relative risk in each study and combine 
study-level measures using random effects meta-analysis 
to allow the underlying true effect to vary across studies.77 
In the one-stage models, we will include study-specific 
intercepts to quantify and account for between-study vari-
ation in baseline risk. We will use random slopes to allow 
the relation between certain cofactors and the risk of CZS 
to vary across populations.
Combining absolute measures of effect, like the risk 
difference, across studies may mask important differ-
ences in the baseline risk.78 We will present estimates of 
the risk difference in a forest plot of study-level estimates 
without presenting a summary meta-analytic estimate. In 
both the one-stage and two-stage analyses, we will use log 
binomial regression models to estimate the relative risk of 
each binary outcome and will use log Poisson regression 
to estimate the relative risk if log binomial models fail to 
converge.79 80 In the two-stage models, we will assess the 
potential for non-linear relationships between continuous 
exposures (viral load) and covariates (eg, gestational age, 
maternal age) by using the Akaike information criteria 
to compare restricted cubic splines with three knots to 
exponential, quadratic and linear terms. In the one-stage 
models, we will use generalised additive mixed models 
(GAMMs) to assess potential non-linearities as the GAMM 
random smoothing parameter addresses the bias/vari-
ance trade-off by penalising the added complexity from 
non-linear terms while accounting for between-study vari-
ation in non-linear effects.81
Joint estimation of multiple nested or otherwise related outcomes 
(multivariate meta-analysis)
Not all studies will have measured all primary or secondary 
outcomes of interest. For example, most studies will have 
measured ventriculomegaly, but may not include values 
for intracranial calcification or ocular abnormalities.9 
This analysis is intended to increase the precision of esti-
mates of the spectrum of CZS abnormalities. Studies that 
do not include the measurement of a given outcome will 
necessarily be excluded from univariate estimates of that 
outcome, but will be included in multivariate models that 
estimate the joint probability of related outcomes. In the 
multivariate models, we will assume that the outcomes that 
are excluded from certain studies are missing at random 
and will incorporate studies by setting the missing obser-
vations and within-study correlations between outcomes 
to zero and will set the within-study variance to a very 
high number such that the artificial value that acts as a 
substitute for the missing outcome will have a negligible 
effect on the meta-analytic estimate from the multivar-
iate model.82 Alternatively, under a Bayesian framework, 
we will model a joint distribution for studies providing 
multiple outcomes and a univariate distribution for 
studies providing a single outcome without needing to 
address the missing within-study correlations and vari-
ance for studies with only one outcome.83 The secondary 
outcomes that will be included in the multivariate analysis 
are listed in table 1.
We will compare generalised linear mixed models 
(GLMMs) where we use one model to analyse nested or 
otherwise related outcomes to the standard univariate 
approach where we apply a separate model to analyse 
each outcome. Multivariate meta-analysis allows for the 
estimation of joint probabilities across multiple outcomes 
and accounts for cross-study and within-study correla-
tion between related outcomes.82 84 Modelling several 
outcomes simultaneously improves the precision over 
univariate models by sharing information about hetero-
geneity and the average effect of the treatment which may 
facilitate inference about the relation between different 
CZS-related outcomes82 85 86 (ie, vermian dysgenesis and 
ocular abnormalities).
Multivariate model to combine estimates from fully and partially 
adjusted studies
A number of longitudinal studies will not include the 
minimal sufficient set of confounders. Estimates from 
partially adjusted studies (that are missing values for 
important confounders) will be combined with fully 
adjusted estimates in a one-stage multivariate meta-anal-
ysis. The one-stage multivariate model allows us to borrow 
information from partially adjusted studies with different 
sets of confounders while ensuring that we control for 
important confounders.82 85
Special considerations for the meta-analysis of cohort studies with 
rare events
Two-stage meta-analytic methods are based on large 
sample approximations and may be unsuitable in the 
context of CZS, which can be considered a rare event.87 88 
Two-stage meta-analysis may be biased when small studies 
are included, the effect of an exposure is very large or the 
outcome is rare, all of which may affect this analysis.89 We 
will highlight any instances when the two-stage meta-an-
alytic estimates may be biased by the aforementioned 
issues and will limit our inference to one-stage anal-
yses in those cases. If we have a number of longitudinal 
studies with zero events, we will focus our inference on 
a one-stage approach to avoid reliance on large sample 
approximations.
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Assessment of study-level and participant-level heterogeneity
Separating within-study and between-study heterogeneity 
is central to assessing participant-level heterogeneity and 
to understanding the relative importance of different 
potential effect measure modifiers.50 We are only able 
to separate within-study and between-study heteroge-
neity across studies that include both levels of the effect 
measure modifier of interest. The presence of clinical 
illness may be related to disease course through viral load 
or be a marker for the strength of the immune system’s 
response to infection. We will conduct a one-stage anal-
ysis of longitudinal studies that include both symptomatic 
and asymptomatic women to assess whether the risk of 
CZS or of the most severe effects of congenital infection 
(miscarriage, fetal loss) differs for clinical and subclinical 
infections. Between-study heterogeneity is reflective of 
study-level differences, while within-study heterogeneity 
may be indicative of clinically important differences. We 
will mean centre covariates included in the interaction 
terms at the study level to separate between-study and 
within-study heterogeneity in our one-stage meta-ana-
lytic estimates of how prior or co-infection with alpha or 
flaviviruses or STORCH pathogens modifies the effect of 
ZIKV infection.90
Heterogeneity in effect estimates will arise from clini-
cally important differences between congenital infections 
or women (effect measure modification) and from study-
level differences in exposure and outcome ascertainment 
(measurement error). With IPD, we are able to jointly 
assess study-level and participant-level heterogeneity.52 
We will incorporate participant-level interaction terms 
in a one-stage analysis that includes random intercepts 
to account for unmeasured study-level factors. We will 
consider random slopes for certain covariates to allow for 
between-study variation in covariate effects across studies. 
Given the difficulty in assessing the total df in mixed 
models, we will apply bootstrapping to assess the approxi-
mate confidence intervals of the pooled interaction terms. 
We will present the analysis of effect measure modifiers in 
accordance with the revised STROBE guidelines.91
Based on our review of research protocols for planned 
or ongoing cohort studies, we expect to include data 
from longitudinal studies with different enrolment 
criteria, exposure and outcome ascertainment, diag-
nostic assays for prior-infections or coinfections and 
measurement of important cofactors. We will include 
measures of study-level sources of heterogeneity (eg, 
diagnostic assay, outcome definitions) as covariates in the 
one-stage regression to assess the variance explained by 
these factors. We will perform a sensitivity analysis where 
we limit our inference to studies with similar inclusion 
criteria and exposure, cofactor and outcome ascertain-
ment to reduce spurious cross-study heterogeneity. While 
two-stage analyses of interaction effects that fail to sepa-
rate between-study and within-study heterogeneity are 
subject to ecological bias90 and our inference about the 
importance of interaction terms will primarily be derived 
from one-stage analyses, we will use a two-stage analysis to 
compare the magnitude of the interaction effects across 
studies. The interaction between certain cofactors and 
ZIKV exposure may not be consistent across studies. In 
the first stage of the two-stage analysis, we will use the 
likelihood ratio test (p<0.05) to assess the importance of 
including interaction terms within each study. Individual 
cohort studies may not have the sample size needed to 
detect clinically important interactions between ZIKV and 
important cofactors. We will also assess whether a certain 
interaction is consistent across studies, while not neces-
sarily statistically significant within individual studies.
Meta-regression and subgroup analyses have limited 
power to detect interactions and can only be used to 
make inference about the relation between the exposure 
and study-level, average values of participant character-
istics.89 92 Studies that are not willing or able to provide 
participant-level data may differ importantly from longi-
tudinal studies whose data is included in the IPD-MA. 
We will apply subgroup analysis to a two-stage analysis 
of effect estimates from studies included in the IPD-MA 
and published estimates from studies that did not partic-
ipate in the IPD-MA to assess whether study-level varia-
tion in recruitment and enrolment criteria, exposure 
and outcome ascertainment and measurement of coin-
fections and other cofactors are important sources of 
heterogeneity in the pooled estimates. Some sources of 
heterogeneity (eg, vector density and feeding patterns; 
DENV serotype) may not be measured and should be 
considered in sensitivity analyses.
Objective 3
 Use information on the relative importance of different effect 
measure modifiers identified in Objective 2 to decompose the 
total effect of ZIKV infection during pregnancy on adverse fetal, 
infant and child outcomes
Some studies suggest that antibody-dependent enhance-
ment related to concurrent or prior DENV infection or 
Japanese encephalitis vaccination may modify the effect 
of ZIKV infection on fetal development. Both the timing 
of exposure to DENV and DENV serotype may contribute 
to regional differences in the strength of the relation 
between ZIKV infection and CZS.28 32 If we find evidence 
in the literature that the effect measure modifier identi-
fied in Objective 2 (eg, DENV) may affect the outcome 
(eg, CZS), we will apply inverse probability of treatment 
weighted-marginal structural models to decompose the 
total effect of ZIKV on the outcome of interest into the 
direct effects of ZIKV infection, the effect of ZIKV infec-
tion mediated by the posited effect measure modifier and 
the effect of the interaction between ZIKV and the effect 
measure modifier.93 94
Objective 4
 Develop and validate a risk prediction tool to inform decision 
making by pregnant women, couples planning a pregnancy and 
healthcare providers and/or resource mobilisation
We will fit one-stage logistic regression models with 
random intercepts to account for differences in the 
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baseline risk within each study. We will apply group Lasso 
regression95 to identify the prognostic variables that 
predict progression to miscarriage, fetal loss and micro-
cephaly. Lasso regression is implemented using L1-penal-
ised estimation. The application of group Lasso ensures 
that the algorithm selects all levels of categorical variables 
by treating corresponding dummy variables as a group 
instead of allowing the model to only select certain levels 
of categorical variables.96 97 The L-1 penalty term allows 
for concurrent consideration of predictors and shrinkage, 
which facilitates variable selection in the context of high 
dimensional data.98 We will standardise included vari-
ables so that all variables use the same scale. We will adopt 
cross-validation on the study level to select the optimal 
tuning parameter (λ) and will adopt restricted maximum 
likelihood (REML) to estimate the variance-covariance 
matrix of the study-level random effects.
Not all studies will have the resources to implement the 
most accurate and reliable ZIKV-related diagnostic tools. 
As part of the data synthesis, we will identify the exposure 
and cofactor diagnostic methods that are most commonly 
applied. As a sensitivity analysis, we will use these diag-
nostic methods to develop a risk prediction model so that 
the model can be applied in regular clinical practice.
Development and external validation of the prediction model
We will apply internal-external cross-validation where we 
rotate the cohort that is used for external validation to 
improve the model’s predictive ability.99 For example, 
given k cohort studies, we will use k-1 cohort studies to 
develop the prediction model and will validate model 
performance by applying the prediction model to a cohort 
that was not used to develop the prediction model. Inter-
nal-external cross-validation allows for the use of all avail-
able data for model development and validation which 
improves model performance and generalisability.100
Evaluation of model performance
We will generate receiver operating characteristic (ROC) 
curves101 102 in the cohort that was not used to develop 
the prediction model to estimate the model’s true-posi-
tive (sensitivity) versus false-positive (1-specificity) rate 
for each binary outcome. These curves will then be 
summarised using the area under the ROC curve (AUC). 
In some instances, the pregnant woman or couple plan-
ning a pregnancy may prefer a more sensitive rather than 
a more specific model. We will present a range of cut-off 
values that maximise sensitivity, specificity or both sensi-
tivity and specificity to facilitate decision making by preg-
nant women or couples planning a pregnancy. We will 
assess the extent to which these thresholds yield consis-
tent sensitivity and specificity across different regions and 
populations. We will use calibration plots to compare the 
observed and predicted probability of the outcome of 
interest within risk quintiles and summarise these plots 
by calculating the total ratio of observed versus expected 
events (O:E ratio) and the calibration slope. Internal-ex-
ternal cross-validation of k studies will result in kAUCs, 
O:E ratios and calibration slopes. We will apply random 
effects meta-analysis to combine estimates of the discrim-
ination and calibration of the kpredictive models. We will 
assess model calibration and discrimination and choose 
the model with the best properties.99 103 We will use boot-
strap validation to evaluate model optimism and will 
follow the TRIPOD statement guidelines for reporting 
the final prediction models.104
step 4. Quantitative bias analysis
Given the complexity and level of measurement error, we 
will conduct a quantitative bias analysis under a Bayesian 
framework where we use a combination of expert 
opinion, laboratory EQA and external and internal 
assessment of the relative accuracy of diagnostic assays 
and other methods for cofactor and outcome ascertain-
ment to inform the prior distributions of bias parame-
ters. Where possible, we will apply frequentist methods 
for quantitative bias analysis105 as a sensitivity analysis and 
will use the GRADE criteria106 to compare the quality of 
the evidence from Bayesian and frequentist models, with 
a focus on how imprecision, inconsistency, indirectness, 
magnitude of effect differ in the Bayesian and frequen-
tist approaches to addressing the myriad sources of bias 
expected to affect these analyses.
Selection bias
Studies or surveillance systems that only recruit or 
test symptomatic pregnant women or studies that only 
enrolled pregnant women who tested positive for ZIKV 
infection are affected by selection bias because selection 
into the study is associated with the exposure.63 This situ-
ation is similar to the inclusion of a single treatment arm 
in a randomised controlled trial. Although data from 
studies that only enrol pregnant women who test positive 
for ZIKV cannot directly inform estimates of the causal 
effect of ZIKV, these data can inform the development 
of prediction models because they contain information 
on the prognosis of ZIKV positive women. Longitudinal 
studies that restrict enrolment to ZIKV positive pregnant 
women may also increase the precision of relative treat-
ment effects by providing more events within ZIKV-ex-
posed pregnant women. Longitudinal studies have 
reported that women who perceive their infants as unaf-
fected by CZS are less likely to participate in follow-up. 
We will consider matching on the propensity score or 
the use of inverse probability of censoring weights107 
and prognostic score analysis108 to account for measured 
determinants of differential loss to follow-up in the aeti-
ological and prognostic models, respectively. Selection 
bias can be induced when we inappropriately adjust for 
a time-varying confounder affected by prior exposure 
(a confounder that also acts to mediate the relation 
between ZIKV infection and adverse fetal, infant or child 
outcomes). We will use G-computation methods to appro-
priately adjust for time-dependent confounders affected 
by prior exposure.109
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Confounding bias
We will adjust for confounders that are unlikely to 
mediate the causal relation between infection during 
pregnancy and adverse infant outcomes (table 1). We will 
estimate each participant’s likelihood of being infected 
during pregnancy, conditional on the study group and 
important confounders, to identify possible violations of 
the positivity assumption. In sensitivity analyses, we will 
apply propensity score matching within studies to ensure 
that important confounders are adequately balanced 
across exposure groups. Despite the prospective, collab-
orative development of a standardised research protocol 
for ZIKV cohort studies of pregnant women, confounders 
and effect measure modifiers may be defined differently 
across studies or not measured in certain studies. We will 
develop a detailed codebook that reflects the heteroge-
neity in confounder definitions and report on this hetero-
geneity in our analyses.
Measurement (ie, detection, misclassification) bias
Despite efforts to harmonise case definitions across 
studies with the prospective development of a stan-
dardised protocol for cohorts of pregnant women and 
their infants,60 the case definitions, diagnostic tools and 
algorithms used to ascertain ZIKV infection, cofactors and 
CZS-associated outcomes vary across studies.110 The liter-
ature on the accuracy of ZIKV-related and DENV-related 
assays is evolving rapidly.30 111 Prior to initiating our anal-
yses, we will synthesise the current evidence on the sensi-
tivity and specificity of different assays for ZIKV diagnosis, 
for the assessment of concurrent or prior DENV infections 
and for estimating the time of infection, among other 
relevant factors. The WHO standardised protocol for 
ZIKV-related cohorts of pregnant women includes WHO 
recommendations on the screening and assessment of 
neonates and infants with intrauterine ZIKV exposure;112 
we will compare study-level outcome definitions with the 
standardised WHO definitions. The role of heterogeneity 
related to case definitions and diagnostic tools will be 
explored through both frequentist and Bayesian methods. 
In the frequentist approach, we will: (1) include categor-
ical or continuous markers of sensitivity and specificity of 
diagnostic tools as study-level covariates in the one-stage 
analyses and (2) apply diagnostic tool specific-subgroup 
analysis to both the one-stage and two-stage meta-analysis 
of effect measures from different studies. In the Bayesian 
approach, we will use a combination of expert opinion 
and data from external and internal validation studies to 
inform the probability distributions of bias parameters.113
Missing data
Missing data at the study level, as when confounders are 
not measured in certain studies, is a well-known chal-
lenge of IPD-MA114 115 and a likely source of residual 
confounding. In keeping with current recommendations 
for addressing missingness in IPD-MA, we will apply new 
methods for multilevel multiple imputation to account 
for missing values.116 As a sensitivity analysis, we will 
impute missing participant-level data in each study sepa-
rately and use multivariate meta-analysis to combine data 
across studies that have and have not measured important 
host-level and environmental-level cofactors.
Publication bias
IPD-MA may have a lower risk of publication bias than 
AD-MA because they include data from unpublished 
studies.114 We have tried to ensure that the ZIKV IPD 
Consortium includes representatives from all of the 
academic and government institutions responsible for 
planned or ongoing ZIKV-related longitudinal studies 
of pregnant women and their infants. We expect that 
Consortium members will identify most ZIKV longitu-
dinal studies and active surveillance systems of preg-
nant women and their infants, regardless of publication 
status, and we will conduct a systematic review to identify 
additional longitudinal studies and active surveillance 
systems. The degree of publication bias will be assessed 
visually by reviewing the asymmetry of study-level esti-
mates from published and unpublished studies using 
funnel plots that compare log RR to the corresponding 
studies’ sample size.117
We will convene a group of patient advocates to eval-
uate the ethical implications and utility of the risk strati-
fication tool.
dIsCussIon
The application of IPD-MA to an emerging pathogen 
presents an important opportunity to harness global 
collaboration to inform the development of recommen-
dations for pregnant women, couples planning a preg-
nancy and public health practitioners. While IPD-MA 
offers real benefits compared with AD-MA or to the infer-
ence possible with individual cohort studies, the ability 
of IPD-MA to inform public health practice is directly 
related to the quality of the exposure, cofactor and 
outcome ascertainment in the original cohort studies. 
Statistical methods for IPD-MA were developed in the 
context of clinical research and randomised control trials. 
These methods needs to be adapted to account for the 
myriad sources of uncertainty and bias that affect observa-
tional research, especially for field epidemiology studies 
conducted as part of the research response to unknown 
or emerging pathogens.
Historically, arboviruses and other neglected tropical 
diseases have been understudied because the burden 
of disease falls on under resourced populations in the 
Global South.118 In the context of ZIKV, the unequal 
distribution of risk is coupled with inequities in access to 
preventative measures like modern contraception and to 
critical clinical and therapeutic care for infants affected 
by microcephaly and ZIKV-related neurological disor-
ders. Each case of microcephaly is associated with a loss 
of 29.95 disability adjusted life years (DALYs) and treat-
ment costs ranging from US$91K to US$1 million.119 To 
put these figures into perspective, the yearly per capita 
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income in Pernambuco, the Brazilian state with one of 
the highest burdens of CZS, is US$3471.120
There is no vaccine for ZIKV and the only treatment 
is supportive.58 There have been numerous calls for data 
sharing121 122 and cooperation between governments 
and academic institutions,54 123 and public and private 
charities have pledged significant financial support to 
improve our understanding of ZIKV epidemiology and 
to develop a vaccine or small molecule prophylaxis to 
decrease the risk of infection. In the wake of the Ebola 
epidemic, the global response to ZIKV has been charac-
terised by unprecedented levels of international cooper-
ation. In the absence of a ZIKV vaccine or prophylaxis, 
international leaders in ZIKV research have formed the 
ZIKV IPD Consortium to identify, collect and synthesise 
IPD from longitudinal studies of pregnant women that 
measure ZIKV infection during pregnancy and fetal, 
infant and child outcomes. These data will be used to 
quantify the absolute risk of ZIKV-related pregnancy 
complications with the goal of aiding women and their 
families in making difficult reproductive decisions and 
with helping public health systems prevent and quantify 
the burden of congenital Zika infection.
Challenges of developing and conducting an individual 
participant data-meta-analysis in the context of an emerging 
pathogen
Ideally, researchers prespecify confounders, effect 
measure modifiers and plans for subgroup or sensi-
tivity analyses in their research protocol. In the context 
of Zika, our understanding of the virus is changing so 
rapidly that analysis plans may change significantly 
despite our best efforts to review the latest evidence on 
transmission, immunological response, diagnostic assays, 
vector biology and basic ZIKV epidemiology. Our ability 
to appropriately account for measurement error will play 
a critical role in the accuracy of estimates for the risk of 
CZS and other adverse fetal, infant and child outcomes. 
This is one of the first instances where an IPD-MA has 
been used to address public health concerns in the 
context of an emerging pathogen. We expect that best 
practices and lessons learnt from this IPD-MA can be 
used to facilitate the formation of research collabora-
tions to streamline the public health response to future 
epidemics.
Patient and public involvement
In keeping with guidelines for public involvement in 
research,124 knowledge users (ie, women of reproduc-
tive age and their families, clinicians) will be consulted 
at each stage of this research. The research question and 
protocol were designed with feedback from clinicians who 
treat pregnant women in ZIKV-endemic areas and infants 
and children affected by CZS. Focus groups that include 
women of reproductive age in ZIKV-endemic areas will be 
used to evaluate the ethical implications and utility of the 
risk stratification tool in three countries.
EthICs And dIssEMInAtIon
This IPD-MA protocol has been deemed exempt from 
ethical review by the WHO Ethics Review Committee 
and the Emory University Institutional Review Board. 
Individual longitudinal studies will provide documenta-
tion of ethics review prior to sharing their deidentified, 
participant-level data. The WHO has developed guid-
ance for data sharing in public health emergencies or in 
the context of emerging pathogens.125 Sharing deiden-
tified data for IPD-MA is generally considered exempt 
from ethical review if the objectives of the IPD-MA are 
in keeping with the objectives of the original studies.126 
Individual research studies and consortia will secure addi-
tional ethics review and/or legal guidance on the sharing 
of deidentified, subject-level data as needed. The results 
of this analysis will be published under the ZIKV IPD 
Consortium name and will include a list of the names of 
key investigators from each study that contributed data 
for that analysis and researchers who contributed to the 
analysis or writing at the end of the publication. Findings 
from the proposed analysis will be shared via national and 
international conferences; existing platforms for dissem-
ination of ZIKV-related research (eg, The Global Health 
Network) and through publication in open access, 
peer-reviewed journals.
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